Not yet recruiting
Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
NCT07493330
- Conditions
- PTCL, Refractory
- Locations
-
Not specified
Clinical trial condition
Refractory
Explore clinical trials studying Refractory. Study availability and eligibility vary by location and protocol.
17 public trials
9 recruiting studies
Refractory trial results
Not yet recruiting
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
NCT07287228
- Conditions
- Anemia, Anemia, Aplastic, Aplastic Anemia, +10 more
- Locations
-
- Institute of Hematology & Blood Diseases Hosptial, Chinese Academy of Medical Science and Peking Union Medical School Tianjin, Tianjin Municipality, China
Not yet recruiting
Long-term Evaluation of Percutaneous Endoscopic Caecostomy in Refractory Constipation
NCT07160192
- Conditions
- Constipation, Pathological Conditions, Signs and Symptoms, Refractory, +2 more
- Locations
-
- Nantes University Hospital Nantes, Loire-Atlantique, France
Active, not recruiting
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
NCT03179930
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Northwestern University (Data Collection Only) Evanston, Illinois, United States
- Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
Active, not recruiting
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
NCT05911321
- Conditions
- Aging, Blood Protein Disorders, Cardiovascular Diseases, +20 more
- Locations
-
- Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
- Atrium Health Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States
Active, not recruiting
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
NCT03085173
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +17 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States
Completed
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
NCT00752518
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
- Locations
-
Not specified